I couldn’t have asked for a better partner than Dr. Victoria Hall who co-led this work with me. Thanks to the Ajmera Transplant Centre and PSI Foundation for their funding support, to Dr. Lavoie & his team, our UHN colleagues, and to the participants whose generosity made this work possible.

Our first publication addressing RSV vaccination in transplant recipients is now available in Clinical Microbiology and Infection: www.sciencedirect.com/science/arti... We found marginal rates of seroconversion but robust CD4+ T cell responses after a single dose of adjuvanted vaccine.

Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: An Interventional Cohort Study

Allogeneic hematopoietic cell transplant (alloHCT) and lung transplant (LT) recipients are at highest risk for severe respiratory syncytial virus (RSV…

sciencedirect.com

Pleased to share our article: adj RSV vaccination in high-risk transplant pts - significant NAb and T cell response observed post vaccination. Seroconversion modest in 50% lung transplant and 33% alloHCT. @transplant-uhn.bsky.social @cmijournal.bsky.social www.sciencedirect.com/science/arti...

Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: an interventional cohort study

Allogeneic haematopoietic cell transplant (alloHCT) and lung transplant (LT) recipients are at highest risk for severe respiratory syncytial virus (RS…

sciencedirect.com

Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial url: academic.oup.com/jid/article-...

Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial

In an in-depth immunological analysis of alternate influenza vaccination strategies in high-risk patients receiving therapy for hematological malignancy, p

academic.oup.com

A/Prof Ben Teh presenting his and NCIC PhD candidate Dr Tori Halls work on respiratory viruses in people with haem malignancy at #escmidglobal flash poster session. RSV in particular associated with more severe disease

Two patients with refractory myeloma who had excellent antitumor responses to cilta-cel CAR T-cell therapy later had T-cell lymphomas that contained the lentivirus construct used to generate the CAR T-cell product. Brief Report on the CARTITUDE-4 trial: nej.md/4gA6G27 #MedSky #Hematology

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma | NEJM

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel (cil...

nej.md

If you care for patients with suspected tuberculosis, this excellent online tool helps assess the risk of active TB disease and potential medication side effects. Link: www.TSTin4D.com From colleagues at McGill. #IDSky #MedSky

Congratulations Tori!

Tori Hall@victoriahall.bsky.social · 2y ago

Very proud of this hard work & team effort from all involved! Limited benefit of adjuvanted flu 💉 & 2 vs 1 dose in pts w/ MM, CLL or NHL. @ncicancer.bsky.social @petermaccc.bsky.social @benwteh.bsky.social @trubianojason.bsky.social @michyong.bsky.social @nejm.org www.nejm.org/doi/full/10....

💉 One flu shot is enough! New research from @benwteh.bsky.social & @victoriahall.bsky.social shows a single flu vaccine dose protects non-transplant blood cancer patients. Simplified care + better vaccine use = big win for vulnerable patients! Learn more: www.petermac.org/about-us/new...

Very proud of this hard work & team effort from all involved! Limited benefit of adjuvanted flu 💉 & 2 vs 1 dose in pts w/ MM, CLL or NHL. @ncicancer.bsky.social @petermaccc.bsky.social @benwteh.bsky.social @trubianojason.bsky.social @michyong.bsky.social @nejm.org www.nejm.org/doi/full/10....

Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM

In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.

nejm.org

Practice affirming results from our team @victoriahall.bsky.social @ncicancer.bsky.social - No additional benefit from second influenza vaccine dose/adjuvant vaccines in non-HCT haematology patients. #TxID #IDsky #medsky www.nejm.org/doi/full/10....

Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM

In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.

nejm.org

Hello to the #IDSky and #TxIDSky community! AST IDCOP is excited to announce our presence on Bluesky. @astinfo.bsky.social